Lanreotide

立即咨询

Lanreotide

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:	108736-35-2
规格:	≥98%

包装与价格：

包装	价格(元)
5mg	电议
10mg	电议
25mg	电议
50mg	电议
100mg	电议
250mg	电议

产品介绍

理化性质和储存条件

	Name: Lanreotide CAS#: 108736-35-2 (free base) Chemical Formula: C54H69N11O10S2 Exact Mass: 1095.467 Molecular Weight: 1096.33
Storage	-20℃ for 3 years in powder form
Storage	-80℃ for 2 years in solvent
Technical Information	Synonym: Somatulin; Somatuline; Lanreotide; Ipstyl; BIM23014; Lanreotide Autogel. Chemical Name: (4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-19-((R)-2-amino-3-(naphthalen-2-yl)propanamido)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-10-(4-aminobutyl)-16-(4-hydroxybenzyl)-7-isopropyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide InChi Key: PUDHBTGHUJUUFI-SCTWWAJVSA-N InChi Code: 1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)/t30-,38-,40+,41+,42-,43+,44+,45+,46+/m1/s1 SMILES Code: CC([C@@H]1NC([C@@H](NC([C@H](NC([C@@H](NC([C@@H](NC([C@@H](Cc(cc2)cc3c2cccc3)N)=O)CSSC[C@@H](C(N[C@H](C(N)=O)[C@H](O)C)=O)NC1=O)=O)Cc4ccc(O)cc4)=O)Cc(c[nH]5)c6c5cccc6)=O)CCCCN)=O)C

实验参考方法

In Vitro	Lanreotide (BIM 23014) (100 nM; 24-48 h) combines with radiation increasing in apoptotic sub-G1 proportion[1]. Lanreotide results in a dose-dependent decrease in GH3 cell colony forming units. Lanreotide at concentrations of 1, 10, 100, and 1000 nM results in cell survival rates of 75, 56, 39 and 27% respectively. The IC50 is 57 nM[1]. Lanreotide inhibits GH-secreting pituitary adenoma cell proliferation and hormone release in vitro[2].
In Vivo	Lanreotide (2.5-10mg/kg; s.c.; daily for 5 days) results in tumor growth inhibition[1]. Animal Model: Male nude mice, 8 weeks old and 20–25 g in body weight (GH3 tumor-bearing nude mice)[1] Dosage: 2.5, 5, 10 mg/kg Administration: Subcutaneous; daily for 5 days Result: Produced tumor growth inhibition.

In Vitro

Lanreotide (BIM 23014) (100 nM; 24-48 h) combines with radiation increasing in apoptotic sub-G1 proportion[1]. Lanreotide results in a dose-dependent decrease in GH3 cell colony forming units. Lanreotide at concentrations of 1, 10, 100, and 1000 nM results in cell survival rates of 75, 56, 39 and 27% respectively. The IC50 is 57 nM[1]. Lanreotide inhibits GH-secreting pituitary adenoma cell proliferation and hormone release in vitro[2].

In Vivo

Lanreotide (2.5-10mg/kg; s.c.; daily for 5 days) results in tumor growth inhibition[1]. Animal Model: Male nude mice, 8 weeks old and 20–25 g in body weight (GH3 tumor-bearing nude mice)[1] Dosage: 2.5, 5, 10 mg/kg Administration: Subcutaneous; daily for 5 days Result: Produced tumor growth inhibition.